Covid-19 roundup: Yet more doses of the AstraZeneca-Oxford vaccine; A second randomized hydroxychloroquine study fails
Another gene therapy company is offering its facilities to the Covid-19 fight.
Oxford Biomedica, a 90s-era spinout of Oxford University, has
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
